New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2013
14th Annual Advances in Genome Biology and Technology Meeting is being held on Marco Island, Florida on February 20-23.
News For A;RHHBY;PKI;LIFE;ILMN;QGEN;PACB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 1, 2015
18:43 EDTPACBPacific Biosciences discloses $20M milestone payment
Pacific Biosciences disclosed in a regulatory filing, that on September 23, 2013, Pacific Biosciences of California, entered into a Development, Commercialization and License Agreement with F. Hoffman-La Roche, pursuant to which the company: agreed to develop diagnostic products for clinical use including sequencing systems and consumables based on the company's proprietary Single Molecule, Real-Time, or SMRT, technology; granted Roche an exclusive right to commercialize, and an exclusive license to sell, the developed diagnostic products for clinical use, the exclusivity of which is contingent on achieving sales minimums to be established in the future and contingent on Roche not selling for clinical use any new sequencing instrument that competes with any diagnostic instrument system developed under the Agreement; and agreed to manufacture and supply certain products intended for clinical use as the exclusive supplier to Roche. Pursuant to the Agreement, the company received from Roche a non-refundable up-front payment of $35M and is eligible to receive up to an additional $40M based upon the achievement of development milestones. The Agreement has an initial term of 13 years and provisions allowing Roche 5-year renewals. On November 30, the company achieved the final development milestone under the Agreement, entitling the Company to receive an additional payment of $20M from Roche. Pacific Biosciences has now earned the full $40M of potential milestone payments pursuant to the Agreement.
10:35 EDTQGEN, ILMN, ALeerink life science tools analyst holds an analyst/industry conference call
Subscribe for More Information
08:45 EDTRHHBYRoche has a conference call hosted by JPMorgan
Subscribe for More Information
November 30, 2015
10:05 EDTRHHBYRoche management to meet with JPMorgan
Subscribe for More Information
07:44 EDTPKIRadiological Society of North America to hold annual meeting
Subscribe for More Information
November 24, 2015
16:00 EDTAOptions Update; November 24, 2015
iPath S&P 500 VIX Short-Term Futures up 13c to 19.04, Option volume leaders: AAPL FB NFLX BAC PFE AMZN CHK TWTR GE SUNE DE AGN AAL MSFT INTC X BABA A
15:38 EDTAOptions with increasing volume: SUNE HPQ TSM PMCS TSO EPI A DE CREE
November 22, 2015
15:14 EDTRHHBYExelixis confirms Phase 3 data on Cotellic with Zelboraf for melanoma
Subscribe for More Information
15:09 EDTRHHBYGenentech reports data on Cotellic with Zelboraf for treatment of melanoma
Genentech, a member of the Roche Group, announced data from the pivotal coBRIM study, showing that Cotellic, or cobimetinib, in combination with Zelboraf, or vemurafenib, helped people with BRAF V600E and V600K mutation-positive unresectable or metastatic melanoma live "significantly longer" than with Zelboraf alone, according to the company. Cotellic plus Zelboraf reduced the risk of death by 30% compared to Zelboraf alone and helped people live a median of nearly two years, with 74.5% of BRAF V600 patients alive at one year and 48.3% alive at two years. Ongoing study monitoring did not identify any new safety signals. The company noted that an approval decision on Cotellic from the European Commission is expected before year end.
November 20, 2015
07:56 EDTILMNIllumina has a path back to $200 per share, says Cowen
Subscribe for More Information
November 19, 2015
16:10 EDTAAgilent increases cash dividend to 11.5c per share
Subscribe for More Information
November 18, 2015
08:28 EDTRHHBYLeerink to hold a bus tour
Subscribe for More Information
08:11 EDTRHHBYIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
November 17, 2015
08:43 EDTAAgilent pullback after earnings a buying opportunity, says Cowen
Cowen said any pullback in Agilent after its Q4 earnings report would be a buying opportunity. Even though guidance was lower than expected, the firm still thinks 2017 targets are achievable. Cowen maintained its Market Perform rating and $39 price target on Agilent shares.
07:34 EDTRHHBYOphthotech to hold a conference call
Subscribe for More Information
06:08 EDTRHHBYRoche subsidiary to participate in Ophthotech and Novartis agreement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use